HighTower Advisors LLC Increases Stock Position in Omeros Co. (NASDAQ:OMER)

HighTower Advisors LLC raised its position in Omeros Co. (NASDAQ:OMER) by 7.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,339 shares of the biopharmaceutical company’s stock after acquiring an additional 4,000 shares during the quarter. HighTower Advisors LLC owned approximately 0.10% of Omeros worth $235,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of OMER. BNP Paribas Financial Markets grew its stake in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the last quarter. SPC Financial Inc. purchased a new stake in Omeros in the 3rd quarter worth approximately $77,000. SG Americas Securities LLC bought a new stake in shares of Omeros in the 3rd quarter worth approximately $80,000. AQR Capital Management LLC purchased a new position in shares of Omeros during the second quarter valued at approximately $105,000. Finally, Rhumbline Advisers raised its holdings in shares of Omeros by 6.1% during the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

OMER has been the topic of several recent analyst reports. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Price Performance

NASDAQ:OMER opened at $10.00 on Wednesday. The firm’s 50-day moving average price is $7.21 and its 200-day moving average price is $5.24. The company has a market capitalization of $579.50 million, a PE ratio of -4.33 and a beta of 1.97. Omeros Co. has a 1-year low of $2.61 and a 1-year high of $13.60.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.